Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a signal for tumorigenesis, specifically thyroid and pancreatic cancers, with risk profiles varying significantly by patient age, sex, and body weight.
If you are considering or using a GLP-1 medication (like Ozempic or Wegovy), be aware that there is a detected signal for thyroid and pancreatic tumors in large-scale reporting databases. This risk is not uniform: it appears more frequently in women (thyroid) and older men (pancreas). You should discuss your specific age, sex, and family history with your doctor to weigh these potential risks against the significant benefits of blood sugar and weight management.
Notably, 7457 cases involved benign, malignant, and unspecified tumors (PRR 0.5). Further analysis revealed that the risk of GLP-1RA–associated tumorigenesis varied by age, sex, and weight, suggesting that tumorigenesis risk differed in specific subpopulations.
Why this rating
Based on FAERS spontaneous reporting data (observational, prone to reporting bias), not randomized controlled trials.
Source
Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations
Zhenhan Li et al. · Journal of Diabetes Research · 2026
DOI 10.1155/jdr/8893769
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →